Vectura Group will begin a study in Europe later this calendar year for Favolir, its investigational product for severe, uncontrolled asthma.This group said the decision underlines the company's planned strategy for a broad European development programme for Favolir, rather than a country-specific approach.It follows a recent meeting with the German regulator (BfArM) regarding the local development options for the product. Chief Executive Chris Blackwell, said: "The feedback that we received from BfArM is in-line with our own expectations. The constructive dialogue that we have had with the BfArM has helped us in our planning for the upcoming European pivotal trial and we look forward to taking the development of Favolir to the next stage. "Favolir is an important product and is of potentially high value to all stakeholders."Shares fell 8.55% to 131p at 14:58 on Friday.RD